Drug Approval | February 05, 2026
Inspection included drug device combinations covering our recent filing in nasal sprays domain
Operating profit fell 1% in Danish kroner to DKK 127.7 billion but rose 6% at constant exchange rates
The program seeks to boost regulatory predictability, support construction of US-based manufacturing sites
A PRV is a tradable voucher granted by the FDA to encourage the development of new treatments for rare pediatric diseases
Glucon-D maintained its leadership position with a 59% MAT market share
The approved Lacosamide Oral Solution is bioequivalent and therapeutically equivalent to the reference drug and will be manufactured at Indoco’s facility in Verna Industrial Area, Goa
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
